These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

244 related items for PubMed ID: 20301983

  • 1. A randomized double-blind study comparing the efficacy and safety of orlistat versus placebo in obese patients with mild to moderate hypercholesterolemia.
    de Castro JJ, Dias T, Chambel P, Carvalheiro M, Correia LG, Guerreiro L, Marques O, Medina JL, Nobre E, Nunes JS, Pereiraa MC, Polónia J, Portugal J, Raimundo A, Ruas A, da Silva PM, Vasconcelos C, Reis JL, Teles AG.
    Rev Port Cardiol; 2009 Dec; 28(12):1361-74. PubMed ID: 20301983
    [Abstract] [Full Text] [Related]

  • 2. The effects of orlistat on weight and on serum lipids in obese patients with hypercholesterolemia: a randomized, double-blind, placebo-controlled, multicentre study.
    Muls E, Kolanowski J, Scheen A, Van Gaal L, ObelHyx Study Group.
    Int J Obes Relat Metab Disord; 2001 Nov; 25(11):1713-21. PubMed ID: 11753595
    [Abstract] [Full Text] [Related]

  • 3. Effect of orlistat on cardiovascular disease risk in obese adults.
    Swinburn BA, Carey D, Hills AP, Hooper M, Marks S, Proietto J, Strauss BJ, Sullivan D, Welborn TA, Caterson ID.
    Diabetes Obes Metab; 2005 May; 7(3):254-62. PubMed ID: 15811142
    [Abstract] [Full Text] [Related]

  • 4. X-PERT: weight reduction with orlistat in obese subjects receiving a mildly or moderately reduced-energy diet: early response to treatment predicts weight maintenance.
    Toplak H, Ziegler O, Keller U, Hamann A, Godin C, Wittert G, Zanella MT, Zúñiga-Guajardo S, Van Gaal L.
    Diabetes Obes Metab; 2005 Nov; 7(6):699-708. PubMed ID: 16219013
    [Abstract] [Full Text] [Related]

  • 5. Effect of orlistat on weight regain and cardiovascular risk factors following a very-low-energy diet in abdominally obese patients: a 3-year randomized, placebo-controlled study.
    Richelsen B, Tonstad S, Rössner S, Toubro S, Niskanen L, Madsbad S, Mustajoki P, Rissanen A.
    Diabetes Care; 2007 Jan; 30(1):27-32. PubMed ID: 17192328
    [Abstract] [Full Text] [Related]

  • 6. Orlistat use in overweight women with mild hypercholesterolemia.
    Petrogiannopoulos C, Kalogeropoulos S, Latsios GS, Hartzoulakis G, Kalogeropoulos G, Zaharof A.
    Int J Clin Pharmacol Res; 2002 Jan; 22(3-4):85-8. PubMed ID: 12837045
    [Abstract] [Full Text] [Related]

  • 7. Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. European Orlistat Obesity Study Group.
    Rössner S, Sjöström L, Noack R, Meinders AE, Noseda G.
    Obes Res; 2000 Jan; 8(1):49-61. PubMed ID: 10678259
    [Abstract] [Full Text] [Related]

  • 8. Orlistat, a gastrointestinal lipase inhibitor, in therapy of obesity with concomitant hyperlipidemia.
    Micić D, Ivković-Lazar T, Dragojević R, Jorga J, Stokić E, Hajduković Z.
    Med Pregl; 1999 Jan; 52(9-10):323-33. PubMed ID: 10624380
    [Abstract] [Full Text] [Related]

  • 9. Comparison of metabolic effects of orlistat and sibutramine treatment in Type 2 diabetic obese patients.
    Derosa G, Cicero AF, Murdolo G, Ciccarelli L, Fogari R.
    Diabetes Nutr Metab; 2004 Aug; 17(4):222-9. PubMed ID: 15575343
    [Abstract] [Full Text] [Related]

  • 10. Efficacy and safety comparative evaluation of orlistat and sibutramine treatment in hypertensive obese patients.
    Derosa G, Cicero AF, Murdolo G, Piccinni MN, Fogari E, Bertone G, Ciccarelli L, Fogari R.
    Diabetes Obes Metab; 2005 Jan; 7(1):47-55. PubMed ID: 15642075
    [Abstract] [Full Text] [Related]

  • 11. Cholesterol lowering effect of dietary weight loss and orlistat treatment--efficacy and limitations.
    Erdmann J, Lippl F, Klose G, Schusdziarra V.
    Aliment Pharmacol Ther; 2004 Jun 01; 19(11):1173-9. PubMed ID: 15153170
    [Abstract] [Full Text] [Related]

  • 12. Orlistat maintains biliary lipid composition and hepatobiliary function in obese subjects undergoing moderate weight loss.
    Trouillot TE, Pace DG, McKinley C, Cockey L, Zhi J, Häeussler J, Guerciolini R, Showalter R, Everson GT.
    Am J Gastroenterol; 2001 Jun 01; 96(6):1888-94. PubMed ID: 11421247
    [Abstract] [Full Text] [Related]

  • 13. Orlistat increases serum paraoxonase activity in obese patients.
    Audikovszky M, Pados G, Seres I, Harangi M, Fülöp P, Katona E, Illyés L, Winkler G, Katona EM, Paragh G.
    Nutr Metab Cardiovasc Dis; 2007 May 01; 17(4):268-73. PubMed ID: 17134960
    [Abstract] [Full Text] [Related]

  • 14. Effects of orlistat on obesity-related diseases - a six-month randomized trial.
    Guy-Grand B, Drouin P, Eschwège E, Gin H, Joubert JM, Valensi P.
    Diabetes Obes Metab; 2004 Sep 01; 6(5):375-83. PubMed ID: 15287931
    [Abstract] [Full Text] [Related]

  • 15. Long-term weight loss decreases the nontraditional cardiovascular risk factors interleukin-18 and matrix metalloproteinase-9 in obese subjects.
    Madsen EL, Bruun JM, Skogstrand K, Hougaard DM, Christiansen T, Richelsen B.
    Metabolism; 2009 Jul 01; 58(7):946-53. PubMed ID: 19409578
    [Abstract] [Full Text] [Related]

  • 16. Cost-effectiveness of orlistat for the treatment of overweight and obese patients in Ireland.
    Lacey LA, Wolf A, O'shea D, Erny S, Ruof J.
    Int J Obes (Lond); 2005 Aug 01; 29(8):975-82. PubMed ID: 15852050
    [Abstract] [Full Text] [Related]

  • 17. Effect of orlistat in obese patients with binge eating disorder.
    Golay A, Laurent-Jaccard A, Habicht F, Gachoud JP, Chabloz M, Kammer A, Schutz Y.
    Obes Res; 2005 Oct 01; 13(10):1701-8. PubMed ID: 16286517
    [Abstract] [Full Text] [Related]

  • 18. Comparison of the effects of sibutramine and orlistat on obese, poorly-controlled type 2 diabetic patients.
    Chou KM, Huang BY, Fanchiang JK, Chen CH.
    Chang Gung Med J; 2007 Oct 01; 30(6):538-46. PubMed ID: 18350737
    [Abstract] [Full Text] [Related]

  • 19. Short-term administration of orlistat reduced daytime triglyceridemia in obese women with the metabolic syndrome.
    Tzotzas T, Samara M, Constantinidis T, Tziomalos K, Krassas G.
    Angiology; 2007 Oct 01; 58(1):26-33. PubMed ID: 17351155
    [Abstract] [Full Text] [Related]

  • 20. A double-blind randomized placebo-controlled trial of orlistat for the treatment of nonalcoholic fatty liver disease.
    Zelber-Sagi S, Kessler A, Brazowsky E, Webb M, Lurie Y, Santo M, Leshno M, Blendis L, Halpern Z, Oren R.
    Clin Gastroenterol Hepatol; 2006 May 01; 4(5):639-44. PubMed ID: 16630771
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.